3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Recruiting
3
Terminated
1
Not yet recruiting
1
Enrolling by invitation
1
Completed
1
Approved for marketing
1
Active not recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Gastrointestinal
2
Plasma cell
1
Lymphoid
1
Conditions
Neoplasms
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Cholangiocarcinoma
1
Biliary Tract Neoplasms
1
Interventions
Specimen Handling
317
Magnetic Resonance Spectroscopy
275
pembrolizumab
268
Carboplatin
190
Cyclophosphamide
182
Biopsy
175
Cisplatin
164
Gemcitabine
139
Paclitaxel
137
Bevacizumab
122
fludarabine
119
Nivolumab
115
Radiotherapy
114
Oxaliplatin
96
venetoclax
94
Fluorouracil
90
Docetaxel
87
Dexamethasone
86
Capecitabine
86
Drug Therapy
76
Rituximab
74
Pemetrexed
72
Leucovorin
71
durvalumab
70
Radiosurgery
69
Blood Specimen Collection
69
Standard of Care
68
Doxorubicin
64
atezolizumab
62
Radiation
62
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
futibatinib
×
90 days
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled
NCT05727176
2026-05-28
FOENIX-CCA4
Taiho Oncology, Inc.
Phase 2
Recruiting
120 enrolled
NCT05615818
2026-05-19
SAFIR-ABC10
UNICANCER
Phase 3
Recruiting
800 enrolled